Normalization of Exhaled Carbonyl Compounds After Lung Cancer Resection
- PMID: 27293148
- PMCID: PMC5042568
- DOI: 10.1016/j.athoracsur.2016.04.068
Normalization of Exhaled Carbonyl Compounds After Lung Cancer Resection
Abstract
Background: Quantitative analysis of specific exhaled carbonyl compounds (ECCs) has shown promise for the detection of lung cancer. The purpose of this study is to demonstrate the normalization of ECCs in patients after lung cancer resection.
Methods: Patients from a single center gave consent and were enrolled in the study from 2011 onward. Breath analysis was performed on lung cancer patients before and after surgical resection of their tumors. One liter of breath from a single exhalation was collected and evacuated over a silicon microchip. Carbonyls were captured by oximation reaction and analyzed by mass spectrometry. Concentrations of four cancer-specific ECCs were measured and compared by using the Wilcoxon test. A given cancer marker was considered elevated at 1.5 or more standard deviations greater than the mean of the control population.
Results: There were 34 cancer patients with paired samples and 187 control subjects. The median values after resection were significantly lower for all four ECCs and were equivalent to the control patient values for three of the four ECCs.
Conclusions: The analysis of ECCs demonstrates reduction to the level of control patients after surgical resection for lung cancer. This technology has the potential to be a useful tool to detect disease after lung cancer resection. Continued follow-up will determine whether subsequent elevation of ECCs is indicative of recurrent disease.
Copyright © 2016 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
Figures


Similar articles
-
High sensitivity for lung cancer detection using analysis of exhaled carbonyl compounds.J Thorac Cardiovasc Surg. 2015 Dec;150(6):1517-22; discussion 1522-4. doi: 10.1016/j.jtcvs.2015.08.092. Epub 2015 Aug 31. J Thorac Cardiovasc Surg. 2015. PMID: 26412316
-
Quantitative analysis of exhaled carbonyl compounds distinguishes benign from malignant pulmonary disease.J Thorac Cardiovasc Surg. 2014 Sep;148(3):1074-80; discussion 1080-1. doi: 10.1016/j.jtcvs.2014.06.006. Epub 2014 Jun 8. J Thorac Cardiovasc Surg. 2014. PMID: 25129599
-
Breath carbonyl compounds as biomarkers of lung cancer.Lung Cancer. 2015 Oct;90(1):92-7. doi: 10.1016/j.lungcan.2015.07.005. Epub 2015 Jul 19. Lung Cancer. 2015. PMID: 26233567
-
Review of recent developments in determining volatile organic compounds in exhaled breath as biomarkers for lung cancer diagnosis.Anal Chim Acta. 2017 Dec 15;996:1-9. doi: 10.1016/j.aca.2017.09.021. Epub 2017 Sep 13. Anal Chim Acta. 2017. PMID: 29137702 Review.
-
Lung cancer biomarkers in exhaled breath.Expert Rev Mol Diagn. 2011 Mar;11(2):207-17. doi: 10.1586/erm.10.112. Expert Rev Mol Diagn. 2011. PMID: 21405971 Review.
Cited by
-
Detection of Exhaled Volatile Organic Compounds as Noninvasive Biomarkers for Pancreatic Adenocarcinoma.Ann Surg Oncol. 2025 Jun 23. doi: 10.1245/s10434-025-17685-z. Online ahead of print. Ann Surg Oncol. 2025. PMID: 40550959
-
A novel technology to integrate imaging and clinical markers for non-invasive diagnosis of lung cancer.Sci Rep. 2021 Feb 25;11(1):4597. doi: 10.1038/s41598-021-83907-5. Sci Rep. 2021. PMID: 33633213 Free PMC article.
-
The Use of Breath Analysis in the Management of Lung Cancer: Is It Ready for Primetime?Curr Oncol. 2022 Sep 30;29(10):7355-7378. doi: 10.3390/curroncol29100578. Curr Oncol. 2022. PMID: 36290855 Free PMC article. Review.
-
Accuracy and Methodologic Challenges of Volatile Organic Compound-Based Exhaled Breath Tests for Cancer Diagnosis: A Systematic Review and Meta-analysis.JAMA Oncol. 2019 Jan 1;5(1):e182815. doi: 10.1001/jamaoncol.2018.2815. Epub 2019 Jan 10. JAMA Oncol. 2019. PMID: 30128487 Free PMC article.
-
The human volatilome meets cancer diagnostics: past, present, and future of noninvasive applications.Metabolomics. 2024 Oct 7;20(5):113. doi: 10.1007/s11306-024-02180-5. Metabolomics. 2024. PMID: 39375265 Review.
References
-
- Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. - PubMed
-
- Castle P.E. PSA testing for prostate cancer screening. Lancet Oncol. 2015;16:e2–e3. - PubMed
-
- Oken M.M., Hocking W.G., Kvale P.A. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011;306:1865–1873. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical